API- Dulaglutide

Packaging- Solution for Injection in a Single-dose Pen

Strength- 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL

Get an Enquiry


Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used:

  • as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
  • to reduce the risk of major adverse cardiovascular events in adults with type-2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Dosage and Side Effects

The recommended initiating dose of Dulaglutide injection is 0.75 mg injected subcutaneously once weekly, any time of day, with or without meals. Increase the dose to 1.5 mg once weekly for additional glycemic control.

If additional glycemic control is required, increase the dose to 3 mg once weekly after at least four weeks on the 1.5 mg dose.

If additional glycemic control is required, increase the dose to the maximum dose of 4.5 mg once weekly after at least four weeks on the 3 mg dose.

If a dose is missed, administer it as promptly as possible if there are at least 3 days until the next scheduled dose. If less than 3 days remaining prior to the next scheduled dose, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once-in-a-week dosing schedule. Change the day of weekly administration if necessary, as long as the last dose was given 3 or more days before.

The most commonly reported side effects due to Dulaglutide include diarrhea, nausea, vomiting, abdominal pain, and decreased appetite.

Warning and Precautions

  • Use of dulaglutide 1.5 mg/0.5mL or any other dosage strength is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of this drug and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dyspnea, dysphagia, persistent hoarseness).
  • After initiation of dulaglutide, observe patients carefully for signs/symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue treatment. If pancreatitis is confirmed, treatment should not be restarted. dulaglutide has not been assessed in patients with a previous history of pancreatitis. Look for other antidiabetic therapies in patients with a known history of pancreatitis.
  • Patients receiving dulaglutide 3 mg/0.5mL or any other dosage strength together with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including serious hypoglycemia. The risk of hypoglycemia may be reduced by a reduction in the dose of sulfonylurea (or other concomitantly used insulin secretagogue) or insulin.
  • There have been postmarketing results of serious hypersensitivity reactions including angioedema and anaphylactic reactions in patients treated with Dulaglutide. If a hypersensitivity reaction occurs, discontinue treatment; treat promptly per standard of care, and assess until signs/symptoms resolve. Do not use it in patients with a previous hypersensitivity reaction to dulaglutide injection.
  • Angioedema and anaphylaxis have been reported with some other existing GLP-1 receptor agonists. Impose caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist because it is unspecified whether such patients will be predisposed to anaphylaxis with dulaglutide 0.75 mg/0.5mL injection.
  • Impose caution when starting or escalating doses of dulaglutide in patients with renal impairment. Monitor renal function in all patients with renal impairment reporting serious adverse gastrointestinal reactions. Dulaglutide has not been assessed in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not used in these patients.
  • The rapid improvement in glucose control has been related to the temporary worsening of diabetic retinopathy. Patients with a previous history of diabetic retinopathy need to be assessed for progression of diabetic retinopathy.


What is Dulaglutide?

Dulaglutide (Trulicity injection) is recommended for the treatment of type-2 diabetes. It is a kind of injectable therapy, but it is not insulin.

What dosage strengths Dulaglutide is supplied?

It is supplied in 4 dosage strengths, which are as follows:

  • Dulaglutide 0.75 mg/0.5 mL
  • Dulaglutide 1.5 mg/0.5 mL
  • Dulaglutide 3 mg/0.5 mL
  • Dulaglutide 4.5 mg

How is Dulaglutide administered?

Dulaglutide solution supplied in single-dose pens for subcutaneous administration.

What type of drug is Dulaglutide?

Dulaglutide specifically is a type of drug called incretin mimetics.

Is Dulaglutide a GLP-1?

Yes, Dulaglutide specifically is a once-weekly GLP-1 receptor agonist.

Where can I buy Dulaglutide Injection?

You can buy Dulaglutide injection from any authorized wholesaler after getting a prescription from a qualified doctor. It is always better to check the credential of the wholesaler/supplier/exporter before buying the product.

The buyer should check the existing law in their home country before importing the product.